6847.TWO Puriblood Medical Co., Ltd.
- Market cap
- TWD 1.23B
- P/E
- -
- P/B
- 11.20x
- ROE
- -27.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6847.TWO undervalued?
Graham numberThe Graham number of Puriblood Medical Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Puriblood Medical Co., Ltd. fundamental analysis
No fundamental analysis for Puriblood Medical Co., Ltd. yet.
Puriblood Medical Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Puriblood Medical Co., Ltd.
Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan and internationally. The company offers leukoreduction, cell separation, and P-Tex, an anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan.
Full company profilePuriblood Medical Co., Ltd. financial statements
Puriblood Medical Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 3.09M | 38.6M | 54.6M | 137M | 125M | 111M | 82.3M |
| Gross Profit | -357K | 24.4M | 5.60M | 58.7M | 6.52M | 56.8M | 32.3M |
| Operating Income | -21.4M | -3.30M | -35.4M | 7.24M | -50.4M | -2.74M | -33.4M |
| EBITDA | -15.8M | 3.46M | -30.8M | 26.0M | -44.0M | 4.15M | -29.9M |
| Net Income | -20.6M | -2.78M | -38.0M | 16.5M | -51.6M | -5.37M | -39.0M |
| EPS | -2.39 | -0.32 | -3.26 | 1.16 | -3.63 | -0.38 | -2.72 |
| Balance Sheet | |||||||
| Total Assets | 85.5M | 196M | 266M | 321M | 266M | 259M | 237M |
| Total Liabilities | 58.9M | 51.9M | 49.1M | 87.5M | 84.4M | 83.8M | 96.5M |
| Shareholders' Equity | 26.6M | 144M | 216M | 233M | 181M | 175M | 140M |
| Cash & Short-term Investments | 1.67M | 99.8M | 132M | 99.5M | 117M | 86.6M | 60.4M |
| Total Debt | 40.7M | 33.9M | 30.5M | 56.6M | 51.6M | 51.8M | - |
| Cash Flow | |||||||
| Operating Cash Flow | -15.5M | -9.62M | -43.7M | -30.8M | 26.6M | -29.7M | -27.4M |
| Capital Expenditure | 4.17M | 10.1M | 5.09M | 11.5M | 6.35M | 2.06M | 479K |
| Free Cash Flow | -19.7M | -19.7M | -48.8M | -42.3M | 20.3M | -31.7M | -27.9M |
| Ratios | |||||||
| ROE | -77.2% | -1.9% | -17.6% | 7.1% | -28.5% | -3.1% | -27.8% |
| ROA | -24.0% | -1.4% | -14.3% | 5.2% | -19.4% | -2.1% | -16.5% |
| Net Profit Margin | -664.3% | -7.2% | -69.7% | 12.0% | -41.2% | -4.8% | -47.4% |
| Debt to Equity | 1.53x | 0.23x | 0.14x | 0.24x | 0.29x | 0.30x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Puriblood Medical Co., Ltd. dividends
Puriblood Medical Co., Ltd. has not paid dividends in the last 7 fiscal years.
Who owns Puriblood Medical Co., Ltd.
Ownership data of Puriblood Medical Co., Ltd. is not available yet.
Puriblood Medical Co., Ltd. company profile
- Company name
- Puriblood Medical Co., Ltd.
- Ticker
- 6847.TWO
- ISIN
- TW0006847007
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 38
- Fiscal year end
- December
- Address
- No. 11, Industrial East 9th Rd., Hsinchu City, Taiwan, 300096
- Phone
- 886 3 668 7199
- Website
- puriblood.com
About Puriblood Medical Co., Ltd.
Puriblood Medical Co., Ltd. engages in the research and development of blood purification-related medical devices in Taiwan and internationally. The company offers leukoreduction, cell separation, and P-Tex, an anti-fouling technology, which is composed by bio-inspired molecular formula. It is also involved in animal blood transfusion. Puriblood Medical Co., Ltd. was incorporated in 2015 and is based in Hsinchu City, Taiwan.
Puriblood Medical Co., Ltd. management
3- Dr. Yanwen ChenChairman & President
- Prof. Yung ChangFounder & Consultant
- Xiaowen Jiang FangAccounting Supervisor